We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel miRNA Assay Assesses Pancreatic Masses

By LabMedica International staff writers
Posted on 27 Feb 2012
A miRNA test aids physicians in the diagnosis and management of pancreatic ductal adenocarcinoma (PDAC) when cytology is inconclusive.

The test analyzes the expression levels of small, regulatory fine needle aspirate (FNA) molecules known as microRNA’s (miRNA). More...
An algorithm calculates a score between 0 and 1 by measuring the expression levels of seven miRNAs, and this determines whether or not PDAC has been identified.

The Asuragen, Inc. (Austin, TX, USA) miRNA assay, called the miRInform pancreas test, is immediately available in the company's College of American Pathologists (CAP)-accredited (Clinical Laboratory Improvement Amendments (CLIA) laboratory. miRInform pancreas is performed on FNA biopsies of solid lesions of PDAC patients.

“The development and commercialization of miRInform Pancreas for FNA specimens represents another breakthrough for Asuragen and capitalizes on our deep molecular expertise and unsurpassed foundation in using miRNAs for diagnostic and therapeutic applications,” commented Matt Winkler, PhD, CEO of Asuragen. “We believe miRNAs will prove to be highly relevant for many additional cancer diagnostic applications.

Related Links:

Asuragen, Inc.



Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Rapid Sepsis Test
SeptiCyte RAPID
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.